1,819 results on '"RAPEZZI, CLAUDIO"'
Search Results
2. Electrocardiographic abnormalities in patients with cardiomyopathies
3. Chest CT opportunistic biomarkers for phenotyping high-risk COVID-19 patients: a retrospective multicentre study
4. Clinical and genetic profile of patients enrolled in the Transthyretin Amyloidosis Outcomes Survey (THAOS): 14-year update.
5. Restrictive cardiomyopathy
6. Clinical and Prognostic Implications of Right Ventricular Uptake on Bone Scintigraphy in Transthyretin Amyloid Cardiomyopathy
7. Incidence and determinants of atrial fibrillation in patients with wild-type transthyretin cardiac amyloidosis
8. Amyloid seeding as a disease mechanism and treatment target in transthyretin cardiac amyloidosis
9. RNA-targeting and gene editing therapies for transthyretin amyloidosis
10. AI-SCoRE (artificial intelligence-SARS CoV2 risk evaluation): a fast, objective and fully automated platform to predict the outcome in COVID-19 patients
11. Sex Differences in Wild-Type Transthyretin Amyloidosis: An Analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS)
12. Electrocardiographic heterogeneity of patients with variant transthyretin amyloid cardiomyopathy: Genotype-phenotype correlations
13. Prognosis of Transthyretin Cardiac Amyloidosis Without Heart Failure Symptoms
14. Low QRS Voltages in Cardiac Amyloidosis: Clinical Correlates and Prognostic Value
15. Left-to-right ventricular volume ratio and outcome in heart failure with preserved ejection fraction
16. Addendum to ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2—Evidence Base and Standardized Methods of Imaging
17. Progressive brachial plexus enlargement in hereditary transthyretin amyloidosis
18. Heart failure and catheter ablation of atrial fibrillation: Navigating the difficult waters of heart failure phenotypes
19. Critical Comparison of Documents From Scientific Societies on Cardiac Amyloidosis: JACC State-of-the-Art Review
20. Clinical Importance of Left Atrial Infiltration in Cardiac Transthyretin Amyloidosis
21. Coronary calcium score as a predictor of outcomes in the hypertensive Covid-19 population: results from the Italian (S) Core-Covid-19 Registry
22. Stroke volume and myocardial contraction fraction in transthyretin amyloidosis cardiomyopathy: A systematic review
23. Electrocardiography
24. Current evidence on the diagnostic and prognostic role of native T1 mapping in heart diseases
25. Temporal Trends of Wild-Type Transthyretin Amyloid Cardiomyopathy in the Transthyretin Amyloidosis Outcomes Survey
26. Sex-Related Risk of Cardiac Involvement in Hereditary Transthyretin Amyloidosis: Insights From THAOS
27. Coronary and total thoracic calcium scores predict mortality and provides pathophysiologic insights in COVID-19 patients
28. The hidden interplay between sex and COVID-19 mortality: the role of cardiovascular calcification
29. Addendum to ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2—evidence base and standardized methods of imaging
30. Combining New Classes of Drugs for HFrEF: from Trials to Clinical Practice
31. Impact of clinical and subclinical coronary artery disease as assessed by coronary artery calcium in COVID-19
32. Myocarditis in COVID-19 patients: current problems
33. Correction to: ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 2 of 2—Diagnostic criteria and appropriate utilization
34. Efficacy of Tafamidis in Patients With Hereditary and Wild-Type Transthyretin Amyloid Cardiomyopathy: Further Analyses From ATTR-ACT
35. Transcatheter Mitral Valve Repair in Cardiogenic Shock and Mitral Regurgitation: A Patient-Level, Multicenter Analysis
36. Abstract 11962: Cardiopulmonary Exercise Testing Predicts Mortality in Cardiac Amyloidosis: A Systematic Review and Meta-Analysis
37. Transthyretin amyloid cardiomyopathy: An uncharted territory awaiting discovery
38. Wild-type transthyretin cardiac amyloidosis is not rare in elderly subjects: the CATCH screening study.
39. Safety and Tolerability of Neurohormonal Antagonism in Cardiac Amyloidosis
40. POPDC2 a novel susceptibility gene for conduction disorders
41. Low Sensitivity of Bone Scintigraphy in Detecting Phe64Leu Mutation-Related Transthyretin Cardiac Amyloidosis
42. Do we still need X-rays to ablate atrial fibrillation? A novel zero-fluoroscopy workflow
43. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 2 of 2—Diagnostic criteria and appropriate utilization
44. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2—evidence base and standardized methods of imaging
45. Familial Cardiac Amyloidoses
46. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 2 of 2—Diagnostic Criteria and Appropriate Utilization
47. Screening for Transthyretin Amyloid Cardiomyopathy in Everyday Practice
48. State-of-the-art radionuclide imaging in cardiac transthyretin amyloidosis
49. Effects of cardiac resynchronization therapy on right ventricular function during rest and exercise, as assessed by radionuclide angiography, and on NT-proBNP levels
50. Electrocardiographic abnormalities in patients with cardiomyopathies
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.